Sibelium: Advanced Migraine Prophylaxis for Lasting Relief
| Product dosage: 10 mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $1.38 | $41.32 (0%) | 🛒 Add to cart |
| 60 | $0.76 | $82.64 $45.35 (45%) | 🛒 Add to cart |
| 90 | $0.56 | $123.96 $50.39 (59%) | 🛒 Add to cart |
| 120 | $0.45 | $165.28 $53.41 (68%) | 🛒 Add to cart |
| 180 | $0.31
Best per tab | $247.93 $55.43 (78%) | 🛒 Add to cart |
| Product dosage: 5 mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $1.21 | $36.28 (0%) | 🛒 Add to cart |
| 60 | $0.69 | $72.56 $41.32 (43%) | 🛒 Add to cart |
| 90 | $0.48 | $108.85 $43.34 (60%) | 🛒 Add to cart |
| 120 | $0.39 | $145.13 $47.37 (67%) | 🛒 Add to cart |
| 180 | $0.27
Best per tab | $217.69 $49.38 (77%) | 🛒 Add to cart |
Synonyms | |||
Sibelium, with the active ingredient flunarizine dihydrochloride, is a highly selective calcium channel blocker specifically indicated for the prophylactic management of migraine. It represents a cornerstone in preventive neurological therapy, designed to reduce the frequency and severity of migraine attacks by modulating vascular and neuronal calcium influx. This prescription medication is intended for patients experiencing frequent or debilitating migraines that significantly impact quality of life, offering a targeted approach to long-term management under specialist supervision.
Features
- Active ingredient: Flunarizine dihydrochloride 10mg
- Pharmacological class: Selective calcium channel blocker with additional histamine (H1) blocking properties
- Formulation: Oral tablet
- High selectivity for cerebral vasculature over peripheral vessels
- Long half-life allowing for once-daily dosing regimen
- Demonstrated efficacy in clinical trials for migraine prophylaxis
Benefits
- Significantly reduces migraine attack frequency and intensity
- Decreases reliance on acute migraine medications and associated side effects
- Improves overall quality of life by enabling better daily function
- Provides preventive protection with convenient once-daily dosing
- Offers well-established safety profile with extensive clinical experience
- May benefit patients with concomitant vertigo of peripheral origin
Common use
Sibelium is primarily prescribed for the prophylactic treatment of migraine, particularly for patients experiencing two or more debilitating attacks per month that interfere with normal activities. It is indicated for both migraine with and without aura. The medication is typically considered when non-pharmacological approaches and first-line preventive treatments have proven insufficient or unsuitable. Clinical use extends to patients whose migraine pattern demonstrates clear periodicity or who experience particularly severe attacks that warrant preventive intervention. Treatment is generally initiated after thorough neurological assessment and proper diagnosis confirmation.
Dosage and direction
The recommended starting dosage for adult patients is 10mg once daily, taken in the evening to potentially mitigate any sedative effects. For elderly patients (over 65 years) or those with low body weight, a starting dose of 5mg daily may be appropriate. Treatment should be initiated with a gradual titration, and the maintenance dose should be the lowest effective dose, typically between 5mg and 10mg daily. The full therapeutic effect may take several weeks to manifest, and treatment duration should be regularly evaluated, typically every 6 months. Administration should be with water, with or without food, though consistency in timing is recommended. Treatment should not be abruptly discontinued; gradual dose reduction is advised under medical supervision.
Precautions
Patients should be monitored for the development of extrapyramidal symptoms, particularly parkinsonism and depression, especially in the elderly or those with pre-existing risk factors. Regular assessment of body weight is recommended due to potential appetite stimulation and weight gain. Caution is advised when operating machinery or driving until individual response is established, as drowsiness may occur. Liver function should be monitored periodically during long-term treatment. Patients with a history of depressive disorders require careful observation. The medication may mask symptoms of underlying organic brain disorders. Special consideration is needed for patients with cardiac conduction abnormalities or those taking other medications that prolong the QT interval.
Contraindications
Sibelium is contraindicated in patients with known hypersensitivity to flunarizine or any components of the formulation. It must not be used in patients with pre-existing Parkinson’s disease or other extrapyramidal disorders. Contraindications include history of depressive illness, particularly with suicidal tendencies. The medication is not recommended for patients with severe hepatic impairment. It should not be used during pregnancy unless clearly necessary and under strict medical supervision. Concomitant use with other calcium channel blockers is generally contraindicated. The medication is not indicated for children under 18 years of age.
Possible side effects
The most commonly reported adverse reactions include drowsiness (approximately 15-20% of patients), weight gain (10-15%), and fatigue (8-12%). Other frequently observed effects include nausea, dry mouth, and gastrointestinal discomfort. Less common but potentially serious side effects may include extrapyramidal symptoms such as parkinsonism, tremor, or akathisia (1-3%), depressive mood changes (2-4%), and galactorrhea in rare cases. Some patients may experience muscle aches, hypotension, or skin reactions. The incidence of side effects often decreases with continued treatment, and many are dose-dependent.
Drug interaction
Sibelium may potentiate the effects of other central nervous system depressants including alcohol, barbiturates, benzodiazepines, and neuroleptics. Concomitant use with other calcium channel blockers may lead to additive effects and is generally avoided. The medication may interact with drugs that prolong the QT interval, including certain antiarrhythmics, antidepressants, and antipsychotics. Enzyme-inducing anticonvulsants (carbamazepine, phenytoin) may reduce flunarizine concentrations. Conversely, enzyme inhibitors may increase plasma levels. The antihypertensive effect of certain blood pressure medications may be enhanced. Careful monitoring is required when used with other drugs known to cause extrapyramidal symptoms.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent daily dosing is important for maintaining therapeutic levels, so establishing a routine is recommended. If multiple doses are missed, consultation with a healthcare provider is advised before resuming treatment.
Overdose
Symptoms of overdose may include severe drowsiness, agitation, hypotension, bradycardia, and extrapyramidal symptoms. In cases of suspected overdose, immediate medical attention should be sought. Gastric lavage may be considered if presentation is early. Activated charcoal may be administered. Treatment is primarily supportive and symptomatic, with careful monitoring of cardiac function and neurological status. There is no specific antidote for flunarizine overdose. Hemodialysis is unlikely to be effective due to high protein binding and extensive tissue distribution.
Storage
Store at room temperature (15-30°C) in the original container, protected from light and moisture. Keep the medication out of reach of children and pets. Do not use after the expiration date printed on the packaging. Tablets should not be removed from blister strips until immediately before administration. Do not store in bathrooms or other areas with high humidity. Proper disposal of unused medication should follow local regulations, typically through pharmacy take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Sibelium is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual response to treatment may vary, and the prescribing physician will determine the appropriate therapy based on comprehensive medical assessment. Patients should not initiate or discontinue treatment without medical consultation. Always follow the specific instructions provided by your healthcare provider and refer to the official prescribing information for complete details.
Reviews
Clinical studies demonstrate that approximately 60-70% of migraine patients experience at least a 50% reduction in attack frequency with Sibelium prophylaxis. Many patients report significant improvement in quality of life measures, particularly reduced disability during attacks. Neurologists often note its particular effectiveness in patients with menstrual-associated migraine and those with concomitant vertigo. Some reviews highlight the convenience of once-daily dosing compared to other preventive regimens. However, specialists emphasize the importance of careful patient selection and monitoring due to potential side effects, particularly in susceptible populations. Long-term follow-up studies support maintained efficacy with appropriate dose management.